NasdaqGM - Nasdaq Real Time Price USD
Oruka Therapeutics, Inc. (ORKA)
10.58
+0.27
+(2.62%)
As of 3:14:53 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -0.44 | -0.48 | -1.79 | -2.1 |
| Low Estimate | -0.52 | -0.6 | -2.19 | -2.75 |
| High Estimate | -0.31 | -0.33 | -1.26 | -1.49 |
| Year Ago EPS | -- | -1.46 | -3.87 | -1.79 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|
| EPS Est. | -0.32 | -0.98 | -0.47 |
| EPS Actual | -1.46 | -0.49 | -0.4 |
| Difference | -1.14 | 0.49 | 0.07 |
| Surprise % | -351.55% | 50.00% | 15.79% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.44 | -0.48 | -1.79 | -2.1 |
| 7 Days Ago | -0.51 | -0.55 | -2.34 | -2.53 |
| 30 Days Ago | -0.52 | -0.55 | -2.4 | -2.45 |
| 60 Days Ago | -0.52 | -0.55 | -2.4 | -2.45 |
| 90 Days Ago | -0.37 | -0.37 | -3.95 | -1.97 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | 2 | 2 | 2 | 2 |
| Down Last 30 Days | 2 | 2 | 2 | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ORKA | -- | 66.95% | 53.62% | -17.13% |
| S&P 500 | 13.32% | 2.69% | 7.77% | 13.75% |
Upgrades & Downgrades
| Reiterates | Wedbush: Outperform to Outperform | 5/15/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/7/2025 |
| Initiated | Wolfe Research: Outperform | 2/4/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/25/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 10/31/2024 |
Related Tickers
SYRE Spyre Therapeutics, Inc.
15.30
+2.79%
DNTH Dianthus Therapeutics, Inc.
18.74
-2.75%
ZURA Zura Bio Limited
1.0700
-0.93%
SRZN Surrozen, Inc.
8.01
-0.25%
JBIO Jade Biosciences, Inc.
7.58
+2.16%
APGE Apogee Therapeutics, Inc.
39.65
-0.65%
PHVS Pharvaris N.V.
16.65
-0.27%
ELVN Enliven Therapeutics, Inc.
17.27
+2.49%
KYMR Kymera Therapeutics, Inc.
31.16
+3.19%
VRDN Viridian Therapeutics, Inc.
13.70
+6.86%